Extended Data Fig. 2: ARGO study design. | Nature Medicine

Extended Data Fig. 2: ARGO study design.

From: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Extended Data Fig. 2: ARGO study design.

Induction dosing at weeks 0, 2, 4 and 6 of treatment, followed by Q4W treatment from week 8. aNo formal statistical comparisons were made with the ADA ref arm. bPatients in the USA completed the study at week 12. cIn a subgroup of patients with PsO involving ≥3% of BSA at baseline. ACR, American College of Rheumatology; ADA ref, adalimumab reference; BSA, body surface area; IL-17, interleukin-17; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; Q2W, every 2 weeks; Q4W, every 4 weeks; SJC66, 66-swollen joint count; TJC68, 68-tender joint count; TNFi, tumor necrosis factor inhibitor; W, week.

Back to article page